Back to discover
Disease

Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome

Late-stage therapeutic development

Also known as FCTCS, cutaneous telangiectasia and cancer syndrome, familial, familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome, telangiectasia, cutaneous, and cancer syndrome, familial.

22
Clinical trials
1
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones9View all 9
Results posted 3
Results expected 4
Recently completed 1
Other updates 1
+1 more in the activity timeline below
Activity timeline9

Clinical trials

17 sponsors · 1 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
22
All trials
6
Active
17
Late-stage
6
Completed
Late-stage studies

Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer

Phase 3 · Active, not recruiting · University of Birmingham

A Randomized, Open-label, Multicenter, Phase 3 Trial of Ivonescimab Alone or With Ligufalimab Versus Pembrolizumab in First-line Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 3 · Recruiting · Groupe Oncologie Radiotherapie Tete et Cou

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Phase 3 · Active, not recruiting · Radiation Therapy Oncology Group

Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO

Phase 3 · Active, not recruiting · UNICANCER

An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1

Phase 2/3 · Active, not recruiting · BioNTech SE

A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer

Phase 3 · Active, not recruiting · Lisette Nixon
Recently completed

The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3 · Completed · Adlai Nortye Biopharma Co., Ltd.

An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 · Completed · University of California, San Diego

Evaluation of the Efficacy of Aloe-Vera el Versus Bezydamine Hydrochloride in the Treatment of Radiation Induced Oral Mucositis A Randamized Controlled Clinical Trial

Phase 4 · Completed · October 6 University

Phase III Randomized Study With Cisplatinum and Conventional or Adaptive High Dose Radiotherapy for Advanced Head and Neck Cancer

Phase 3 · Completed · The Netherlands Cancer Institute

A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 · Completed · Incyte Corporation

Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

Phase 3 · Completed · Radiation Therapy Oncology Group

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

ATR0.67

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Serine/threonine-protein kinase ATRvia ATR0.67

Reference

Authoritative identity, definition & identifiers.

Synonyms

FCTCS, cutaneous telangiectasia and cancer syndrome, familial, familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome, telangiectasia, cutaneous, and cancer syndrome, familial

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.